BiotechTube
SyntIV

SyntIV

Cambridge, United States· Est.
syntiv.tech
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

SyntIV is a private, early-stage biotech firm applying synthetic biology to create next-generation immunotherapies and biologics. Its technology platform centers on engineering antibodies with extended antigen recognition sites to target occluded viral and cancer proteins, and on developing T cell receptor-mimicking antibodies for cell therapy applications. The company is partially owned by and holds a license from the University of Minnesota, building on foundational research from the Herschhorn Lab. SyntIV appears to be in a pre-revenue, pre-clinical stage, generating early validation through scientific publications while also offering a catalog of research proteins and DNA tools.

OncologyInfectious Diseases

Technology Platform

Synthetic immunology platform for engineering antibodies with extended antigen recognition sites ('penetrating antibodies') and developing T cell receptor (TCR)-mimic antibodies for soluble or cell therapy (CAR) applications.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

SyntIV's platforms target major unmet needs in oncology (solid tumors via TCR-like CARs) and infectious diseases ('undruggable' viral epitopes), representing multi-billion dollar markets.
The company's foundational license from and partial ownership by the University of Minnesota provides a strong IP position and continuous access to cutting-edge academic research.

Risk Factors

The company faces high technical risk in validating its novel antibody engineering approaches in vivo and clinically.
As a pre-revenue, private entity, it is dependent on future fundraising in a competitive capital environment.
It also operates in a crowded and rapidly evolving competitive landscape against larger, well-funded biotechs and pharma.

Competitive Landscape

SyntIV competes in the broad fields of antibody engineering (e.g., AbCellera, Adimab, Distributed Bio) and TCR/CAR-T cell therapy for solid tumors (e.g., Adaptimmune, Immatics, TCR2 Therapeutics). Its niche focus on penetrating antibodies and TCR-mimics places it against companies developing similar modalities, requiring it to demonstrate superior specificity, affinity, or target access to gain traction.

More companies in Cell & Gene Therapy →More companies in United States →